Drug Profile
SNSP 146
Alternative Names: SYGN-146Latest Information Update: 11 Apr 2023
Price :
$50
*
At a glance
- Originator Synedgen
- Developer Anagram Therapeutics; Synedgen
- Class Glycosaminoglycans; Polymers; Polysaccharides; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease